Limitations, agreements, and source contact

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas · Source last updated 2023-03-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

restrictive Agreement

false

point Of Contact

email

Ellen.Napier@pennmedicine.upenn.edu

organization

University of Pennsylvania, Clinical Research Unit, Lymphoma Group

phone

215.279.1972

title

Ellen Napier, CRNP

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice